Literature DB >> 11164155

Effect of complete androgen blockade on pathologic stage and resection margin status of prostate cancer: progress pathology report of the Italian PROSIT study.

A V Bono1, F Pagano, R Montironi, F Zattoni, A Manganelli, F P Selvaggi, G Comeri, G Fiaccavento, S Guazzieri, C Selli, A Lembo, S Cosciani-Cunico, D Potenzoni, G Muto, L Diamanti, A Santinelli, R Mazzucchelli, T Prayer-Galletti.   

Abstract

OBJECTIVES: To compare the pathologic stage and surgical margin status in patients undergoing either immediate radical prostatectomy or surgery preceded by 3 or 6 months of neoadjuvant hormonal treatment (NHT) in a prospective, randomized study.
METHODS: Four hundred thirty-one men with prostate cancer were enrolled in the Italian randomized prospective PROSIT study. The whole-mount sectioning technique was used. By May 1999, the reviewing pathologist had evaluated 303 specimens. One hundred seven patients were untreated before radical prostatectomy was performed, and 114 and 82 patients had been treated for 3 and 6 months, respectively, with complete androgen blockade.
RESULTS: Pathologic organ-confined disease was found in 63.1% of patients with clinical Stage B disease treated with 6 months of NHT versus 61.0% after 3 months of NHT and 37.5% after immediate surgery. Among patients with clinical Stage C tumors, pathologic staging found organ-confined disease in 62.5%, 32.1%, and 11.1% of patients after 6 months of NHT, 3 months of NHT, and immediate surgery, respectively. Three months of NHT produced a significant increase in negative margins both in patients with clinical Stage B and C disease, but the addition of another 3 months of treatment did not significantly improve this result. A lower degree of benefit was observed in patients with clinical Stage C tumors.
CONCLUSIONS: This study shows that complete androgen blockade before surgery is beneficial in men with clinical Stage B disease. The effects are more pronounced after 6 months of NHT than after 3 months.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11164155     DOI: 10.1016/s0090-4295(00)00866-9

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  7 in total

1.  Therapeutic strategies for localized and locally advanced prostate cancer: combining androgen suppression with definitive local therapy.

Authors:  Anthony V D'Amico
Journal:  Rev Urol       Date:  2003

2.  Androgen deprivation therapy: a cornerstone in the treatment of advanced prostate cancer.

Authors:  Michael K Brawer
Journal:  Rev Urol       Date:  2004

Review 3.  Quality of life and economic considerations in the management of prostate cancer.

Authors:  Marco Turini; Alberto Redaelli; Paola Gramegna; Davide Radice
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

4.  Immunohistochemical expression of PDGFR, VEGF-C, and proteins of the mToR pathway before and after androgen deprivation therapy in prostate carcinoma: significant decrease after treatment.

Authors:  Nicolas Kozakowski; Caroline Hartmann; Hans Christoph Klingler; Martin Susani; Peter R Mazal; Anke Scharrer; Andrea Haitel
Journal:  Target Oncol       Date:  2013-11-17       Impact factor: 4.493

Review 5.  Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.

Authors:  S Kumar; M Shelley; C Harrison; B Coles; T J Wilt; M D Mason
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

Review 6.  Cholesterol Metabolic Reprogramming in Cancer and Its Pharmacological Modulation as Therapeutic Strategy.

Authors:  Isabella Giacomini; Federico Gianfanti; Maria Andrea Desbats; Genny Orso; Massimiliano Berretta; Tommaso Prayer-Galetti; Eugenio Ragazzi; Veronica Cocetta
Journal:  Front Oncol       Date:  2021-05-24       Impact factor: 6.244

Review 7.  Early versus late hormonal therapy for prostate cancer.

Authors:  Hiroshi Miyamoto; Edward M Messing
Journal:  Curr Urol Rep       Date:  2004-06       Impact factor: 2.862

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.